Microdeletions of the Y chromosome are the second most frequent genetic cause of spermatogenetic failure in infertile men after the Klinefelter syndrome. The molecular diagnosis of Y-chromosomal microdeletions is routinely performed in the workup of male infertility in men with azoospermia or severe oligozoospermia. Since 1999, the European Academy of Andrology (EAA) and the European Molecular Genetics Quality Network (EMQN) support the improvement of the quality of the diagnostic assays by publication of the laboratory guidelines for molecular diagnosis of Y-chromosomal microdeletions and by offering external quality assessment trials. The present revision of the 1999 laboratory guidelines summarizes the results of a ÔBest Practice MeetingÕ held in Florence (Italy) in October 2003. The basic protocol for microdeletion screening suggested in the 1999 guidelines proved to be very accurate, sensitive and robust. In the light of the recent advance in the knowledge of the Y chromosome sequence and of the mechanism of microdeletion it was agreed that the basic 1999 protocol, based on two multiplex polymerase chain reactions each covering the three AZF regions, is still fully valid and appropriate for accurate diagnosis.
Introduction
Microdeletions of the Y chromosome are a recently discovered cause of spermatogenetic failure resulting in male infertility. After the Klinefelter syndrome, Y-chromosomal microdeletions are the second most frequent genetic cause of male infertility. In the last decade many investigators have described the occurrence of microdeletions in infertile patients around the world and the molecular diagnosis of deletions has become an important diagnostic test in the workup of male infertility (Vogt et al., 1996; Vogt, 1998; Maurer & Simoni, 2000) .
The portion of the male-specific region of the Y chromosome (MSY), comprising 95% of the Y chromosome and flanked by pseudoautosomal regions , which is affected by deletions has been classically subdivided into three regions called AZFa, AZFb and AZFc, respectively (Vogt et al., 1996) . Microdeletions are relatively frequent among infertile men, although the incidence can vary considerably depending on the selection criteria of the patients. Azoospermic men have a higher incidence of microdeletions than oligozoospermic men and consequently deletion frequency found in different laboratories may vary from 2 to 10% (or even higher) reflecting the composition of the study population Krausz et al., 2001) . Typically, routine laboratories receiving referrals from outside institutions, without controlled patient selection, have a much lower incidence, <2%. Deletions of the three AZF regions occur with different frequency. According to the experience of the Institute of Reproductive Medicine in Münster, based on 34 patients with deletions of the Y chromosome, deletions of the AZFc region are the leading group (79% of all deletions), followed by AZFb (9%), AZFbc (6%), AZFa (3%) and AZFabc (ÔXX maleÕ: 3%).
The published data and the experience of the last years showed that diagnostic protocols can be quite different and that inaccurate or wrong diagnoses occur as well, suggesting the necessity of both standardization and quality control (Simoni, 2001) . Therefore, the European Academy of Andrology (EAA) and the European Molecular Genetics Quality Network (EMQN) jointly supported the publication of the ÔLaboratory guidelines for molecular diagnosis of Y-chromosomal microdeletionsÕ and started offering external quality control.
Four years after publication of the guidelines with the now complete knowledge of the sequence of the Y chromosome and of the mechanism of microdeletions (Kamp et al., 2000; Sun et al., 2000; Kuroda-Kawaguchi et al., 2001; Repping et al., 2002) , it was felt that the time for a revision was ripe and the experts in the field convened together with users in a ÔBest Practice MeetingÕ held in Florence (Italy) in October 2003. The results of this meeting and the revised guidelines are now summarized in this paper.
Structure of the male-specific region of the Y chromosome (MSY) The complete physical map and sequence of MSY are now available . This information was obtained by sequencing and mapping 220 BAC clones containing portions of the MSY from one man. The use of only one individual was necessary because, because of the presence of repetitive sequences with only minute differences characterizing the individual copies of each sequence (sequence family variants, SFV), inter-individual allelic variation or polymorphisms would have prevented the accurate mapping of SFV necessary to allocate the BAC clones. Three classes of sequences were found in MSY: X-transposed (with 99% identity to the X chromosome), X-degenerate (single-copy genes or pseudogene homologues of X-linked genes) and ampliconic. Ampliconic sequences are characterized by sequence pairs showing nearly complete (>99.9%) identity, organized in massive palindromes. According to current knowledge, the reference MSY contains 156 transcription units including 78 protein-coding genes encoding 27 proteins. Ampliconic sequences comprise 60 coding genes and 74 non-coding transcription units mostly grouped in families and expressed mainly or only in the testis. Ampliconic sequences recombine through gene conversion, i.e. non-reciprocal transfer of sequence information occurring between duplicated sequences within the chromosome, a process which maintains the >99.9% identity between repeated sequences organized in pairs in inverted orientation within palindromes.
Besides maintaining the gene content, this peculiar organization provides the structural basis for deletions and rearrangements. Today it is believed that deletions almost invariably arise through homologous recombination between identical repeated sequences with loss of the genetic material between them. Considering the architecture of the MSY, several different deletions are hypothetically possible (Yen, 2001) , some of which have indeed been identified in infertile but also in fertile men (Repping et al., 2003; Fernandes et al., 2004) . Those deletions clinically relevant for male infertility, as of today's knowledge, are briefly described below.
Mechanism and type of deletions
Three discrete AZFa, AZFb and AZFc regions were originally characterized by careful mapping of the MSY of a large number of men with microdeletions when the sequence of the Y chromosome was not completely known (Vogt et al., 1996) . Today the sequence of the MSY and the molecular mechanism resulting in microdeletions have been clarified. This resulted in a new model of deletions in which the AZFb and AZFc regions are overlapping. In addition, the AZFb and AZFbc deletions have been suggested to be the consequence of at least three different deletions patterns (Fig. 1) . No consensus about the model and, consequently, nomenclature of deletions has been reached so far. From the practical, clinical point of view this is, however, uninfluential for the prognosis of the patient and, being aware of the current knowledge, either nomenclature can be adopted.
The AZFa region is about 1100 kb long and contains the single copy genes DFFRY (or USP9Y) and DBY. Recent data obtained simultaneously by different groups identify the origin of complete AZFa deletions in the homologous recombination between identical sequence blocks within the retroviral sequences in the same orientation HERVyq1 and HERVyq2 (Blanco et al., 2000; Kamp et al., 2000; Sun et al., 2000) . Within these retroviruses, recombination can occur in either one of two identical sequence blocks (ID1 and ID2), giving rise to two major pattern of deletions slightly different in their precise breakpoints (Kamp et al., 2000 (Kamp et al., , 2001 Sun et al., 2000) . In any case the complete deletion of the AZFa region removes about 792 kb including both USP9Y and DBY genes, the only two genes in AZFa. Deletions involving only the USPY9 gene or the DBY gene have been reported only by one group (Ferlin et al., 1999; Foresta et al., 2000) and not found in >1600 patients tested elsewhere (Silber et al., 1998; Krausz et al., 2003 and references therein) . Moreover, the mechanism responsible for such selective loss has not been elucidated.
The type and mechanism of deletions of the AZFb and AZFc region have been recently clarified as well (Kuroda-Kawaguchi et al., 2001) . Both regions together comprise 24 genes, most of which present in multiple copies for a total of 46 copies. The complete deletion of AZFb removes 6.2 Mb (including 32 copies of genes and transcription units) and results from homologous recombination between the palindromes P5/proximal P1 . The AZFc region includes 12 genes and transcription units, each present in a variable number of copies making a total of 32 copies (Repping et al., 2003) . The classical complete deletion of AZFc, the most frequent pattern among men with deletions of the Y chromosome, removes 3.5 Mb, originates from the homologous recombination between amplicons b2 and b4 in palindromes P3 and P1, respectively and removes 21 copies of genes and transcription units (Kuroda-Kawaguchi et al., 2001) . Deletions of both AZFb and AZFc together occur by to two major mechanisms involving homologous recombination between P5/distal P1 (7.7 Mb and 42 copies removed) or between P4/distal P1 (7.0 Mb, 38 copies removed) .
Therefore, according to the present knowledge, the following recurrent microdeletions of the Y chromosome are clinically relevant and are found in men with oligo-or azoospermia ( Fig. 1 ):
Given the palindromic structure of the MSY and the presence of several amplicons which could undergo recombination, other types of deletions are possible (Yen, 2001) . Some of them have been identified, although their clinical significance has not yet been fully explored (Fernandes et al., 2002; Repping et al., 2003) .
Genotype/phenotype correlation Y microdeletions are specific for spermatogenic failure as no deletions have been reported in a large number of normospermic men (Krausz et al., 2003) . Although ÔfertilityÕ can be compatible with Y deletions, it simply reflects the fact that natural fertilization may occur even with relatively low sperm counts depending on the female partner's fertility status. For this reason, it is more appropriate to consider Y deletions as a cause of oligo/azoospermia rather than cause of ÔinfertililtyÕ.
Deletions of the entire AZFa region as described above invariably result in complete sertoli cell only (SCO) syndrome and azoospermia (Vogt et al., 1996; Krausz et al., 2000; Kamp et al., 2001; Kleiman et al., 2001; Hopps et al., 2003) . Deletions of isolated genes of the AZFa region, involving only the USPY9 gene or the DBY gene were related to a variable testicular phenotype (Ferlin et al., 1999; Foresta et al., 2000) . Such deletions, however, have been described only sporadically and need further confirmation by other groups. The diagnosis of a complete deletion of the AZFa region implies the virtual impossibility to retrieve testicular sperm for intracytoplasmic sperm injection (ICSI).
Complete deletions of AZFb and AZFb+c (P5/proximal P1, P5/distal P1, P4/distal P1) are characterized by a histological picture of SCO or spermatogenetic arrest resulting in azoospermia. Several reports have shown that, similarly to the complete deletions of the AZFa region, no sperm are found upon attempts of testicular sperm extraction (TESE) in these patients Hopps et al., 2003) . As in the case of complete deletions of AZFa, a diagnosis of complete deletions of AZFb or AZFb+c (P5/proximal P1, P5/distal P1, P4/distal P1) is incompatible with sperm retrieval and ICSI should not be recommended to these patients. Deletions of the AZFc region (b2/b4) are associated with a variable clinical and histological phenotype (Reijo et al., 1996; Luetjens et al., 2002; Oates et al., 2002) . In general, AZFc deletions are compatible with residual spermatogenesis. AZFc deletions can be found in men with azoospermia or severe oligozoospermia and, in rare cases, can even be transmitted naturally to the male offspring (Kühnert et al., 2004 and references therein) . In men with azoospermia and AZFc deletion there is a fairly good chance of retrieving sperm from TESE and children can be conceived by ICSI (Kent-First et al., 1996; Mulhall et al., 1997; Jiang et al., 1999; Kamischke et al., 1999; Kleiman et al., 1999; Page et al., 1999; Cram et al., 2000; van Golde et al., 2001; Oates et al., 2002; Peterlin et al., 2002) . The sons of these patients will be AZFc-deleted.
Indications for molecular screening of the Y chromosome Diagnosis of a microdeletion of the Y chromosome permits the cause of the patient's azoospermia/oligozoospermia to be established and to formulate a prognosis. In which patients should molecular screening of the Y chromosome be performed? The world literature, now based on several thousands of patients screened, indicates that, as a rule, clinically relevant deletions are found in patients with azoospermia or sperm concentration <1 · 10 6 /mL. Very rarely, deletions can be found in infertile patients with sperm concentration between 1 and 5 · 10 6 /mL (Maurer & Simoni, 2000; Foresta et al., 2001) . Although the incidence of microdeletions is higher when patients are selected by testicular histology, e.g. SCO (Foresta et al., 2001; Kamp et al., 2001) , no absolute selection criteria can be given according to which patients are candidates for molecular analysis. In general, in patients with chromosomal abnormalities, obstructive azoospermia or hypogonadotropic hypogonadism molecular analysis of the Y chromosome is not indicated but, the usual clinical parameters such as hormone levels, testicular volume, varicocele, maldescended testis, infections, etc. do not have any predictive value (Maurer et al., 2001; Frydelund-Larsen et al., 2002; Oates et al., 2002; Tomasi et al., 2003) . Patients with azoospermia or severe oligozoospermia who may be candidate for ICSI or TESE/ICSI should be offered deletion screening because TESE should not be recommended in cases of complete deletion of the AZFa region, or complete deletion of AZFb or deletions of the AZFb+c regions. Moreover, microdeletions of the AZFc region are transmitted to the male offspring if assisted reproduction is performed (Kent-First et al., 1996; Mulhall et al., 1997; Jiang et al., 1999; Kamischke et al., 1999; Kleiman et al., 1999; Page et al., 1999; Cram et al., 2000; van Golde et al., 2001; Oates et al., 2002; Peterlin et al., 2002) . Therefore, the diagnosis of a deletion has prognostic value and can influence therapeutic options.
Genetic counselling is mandatory in order to provide information about the risk of producing a son with impaired spermatogenesis. However, the exact phenotype cannot be predicted entirely because of the different genetic background and the impact of environmental factors on reproductive functions and on the fertility potential of father and son. Concerns have been raised about the potential risk for the offspring of developing 45,X0 Turner's syndrome and other phenotypic anomalies associated with sex chromosome mosaicism, including ambiguous genitalia. Data on men with Y microdeletions (Siffroi et al., 2000) and in patients bearing a mosaic 46XY/45X0 karyotype with sexual ambiguity and/or Turner stigmata (Patsalis et al., 2002) suggest that some Yq microdeletions are associated with an overall Y chromosomal instability which might result in the formation of 45,X0 cell lines. Until now only 17 male and 18 female ICSI babies born from fathers affected by Yq microdeletions have been reported (Kent-First et al., 1996; Mulhall et al., 1997; Jiang et al., 1999; Kamischke et al., 1999; Kleiman et al., 1999; Cram et al., 2000; van Golde et al., 2001; Oates et al., 2002; Peterlin et al., 2002 ). It appears that the children are phenotypically normal, except for one son born with pulmonary atresia and a hypoplastic right ventricle (Page et al., 1999) and no ambiguous genitalia or Turner syndrome have been observed among them. Considering that embryos bearing a 45,XO karyotype have a higher risk of spontaneous abortion, it would be important to know whether there is a higher incidence of spontaneous abortion among the partners of Y deleted men. Until this information is available, it should be mentioned to the patients with caution.
In general, the indication for molecular diagnosis of Y-chromosomal microdeletions remains an important clinical decision which should be taken case by case and clinicians should decide in which patients they regard this diagnosis as worthwhile and meaningful.
Guidelines for diagnostic testing
Diagnostic testing of deletions is performed by polymerase chain reaction (PCR) amplification of selected regions of the Y chromosome. MSY-specific STS primers amplify both anonymous sequences of the chromosome or genes and can be now mapped precisely . Although the map of the MSY is now known, virtually nothing is known about the role of the individual genes and transcription units in spermatogenesis and their causal role in infertility. It has been shown that using STS primers specific for discrete genes does not increase the detection rate of clinically relevant microdeletions in DNA samples from ICSI candidates (Silber et al., 1998; Krausz et al., , 2001 Peterlin et al., 2002) . In addition, the palindromic/ampliconic structure of MSY makes this region particularly prone to rearrangements and loss of genetic material, which should not necessarily be regarded as pathological microdeletions and might represent relatively common polymorphisms (Repping et al., 2003; Fernandes et al., 2004) . Therefore it remains basically unimportant whether the STS primers used amplify anonymous regions or specific MSY genes. What is important for the diagnosis is that the panel of STS primers are derived from regions of the Y chromosome, which are not polymorphic and are well known to be deleted specifically in men affected by oligo/azoospermia according to the known, clinically relevant microdeletion pattern. The sequence of MSY and the mechanism underlying the microdeletions have shown definitely that a putative fourth AZFd region postulated by Kent-First et al. (1999) and considered in a popular commercial kit does not exist.
PCR format and internal quality control
The PCR amplification of genomic DNA for clinical diagnosis requires strict compliance with good laboratory practice and basic principles of quality control. Guidelines for internal quality control should be carefully followed when implementing the diagnostics of Y-chromosomal microdeletions and can be downloaded at http://www.emqn. org/bpguidelines.php (25.5.04).
In parallel to the patient's DNA sample, a female sample has to be processed as a control for DNA contamination during the whole procedure. Each set of PCR reactions should be carried out at least in duplex or, even better, multiplex PCR. The multiplex format is helpful to distinguish a negative result from a technical failure through the use of an internal control. An appropriate internal PCR control in AZF diagnostics is the ZFX/ZFY gene because the primers amplify a unique fragment both in male and female DNA, respectively. External positive and negative controls must be run in parallel with each multiplex, i.e. with each set of primers. Appropriate positive and negative controls are a DNA sample from a man with normal spermatogenesis and from a woman, respectively. The DNA sample from a normal man controls for sensitivity and specificity of the assay. The female DNA sample controls for specificity and for contamination. In addition, a water sample, which contains all reaction components but water instead of DNA, must be run with each set of primers. The water sample controls for reagent contamination.
In summary, the diagnostics of Y-chromosomal microdeletions should be performed by multiplex (at least duplex) PCR amplification of genomic DNA, using the ZFX/ZFY as internal PCR control. A DNA sample from a fertile male and from a women and a blank (water) control should be run in parallel with each multiplex.
Basic set of STS primers
In principle, the analysis of only one non-polymorphic STS locus in each AZF region is sufficient to determine whether any STS deletion is present in AZFa, AZFb or AZFc. However, analysing two STS loci in each region reinforces diagnostic accuracy, as deletions involve welldefined regions including many STS loci. Therefore, the concept that at least two STS loci in each AZF region should be analysed remains valid. Based on the experience of many laboratories and the results of external quality control and considering the multiplex PCR format, the first choice of STS primers recommended in the first version of the guidelines remains basically valid. These primers include:
For AZFa: sY84, sY86 For AZFb: sY127, sY134 For AZFc: sY254, sY255 (both in the DAZ gene) These STS primers have been shown to give robust and reproducible results in multiplex PCR reactions by several laboratories and in external quality control trials. Moreover, the SRY gene should be included in the analysis as a control for the testis-determining factor on the short arm of the Y chromosome and for the presence of Y-specific sequences when the ZFY gene is absent (e.g. in XX males).
In summary, the set of PCR primers which should be used in multiplex PCR reactions as best choice for the diagnosis of microdeletion of the AZFa, AZFb and AZFc region includes: sY14 (SRY), ZFX/ZFY, sY84, sY86, sY127, sY134, sY254, sY255. The location of these primers on the Y chromosome is indicated in Fig. 1 .
The sequence of the primers and an example of a PCR protocol are reported in the Appendix A and B. The use of this primer set will enable the detection of almost all the clinically relevant deletions and of over 95% of the deletions reported in the literature in the three AZF regions and is sufficient for routine diagnostics. Adoption of this favourite set of primers by all laboratories is strongly recommended as it allows a minimal standardization and good comparison of laboratory performance and inter-laboratory variability.
Significance of the basic primer set and extension analysis AZFa The molecular analysis of the AZFa region involves the use of the two STS markers sY84 and sY86. Both markers are located upstream of the USPY9 and DBY genes and are anonymous. According to the pathogenic mechanism of the deletion and current experience, once a deletion of both sY84 and sY86 is detected, the probability of dealing with a complete deletion approaches 100%. However, as AZFa deletions are rather rare and it cannot be excluded that even more rare, still unknown deletion patterns exist, when such a deletion if found it is advisable to complete diagnosis by determining whether the deletion is complete or not.
As indicated in the previous guidelines , determination of the extension of the deletion (complete/not complete) can be performed by using the STS primers sY82(present), sY83(absent) for the proximal border and sY87(absent), sY88(present) for the distal border. A more sophisticated determination of the breakpoints can be obtained with the protocol suggested by Kamp et al. (2001) .
If only one of the two AZFa STS loci (only sY84 or only sY86) is deleted and amplification failures can be excluded, the AZFa region should be studied in more detail testing for the presence/absence of the two AZFa genes (DBY and USP9Y) and the borders according to the map provided by Kamp et al. (2001) . This event, however, is presently considered to be extraordinarily rare.
AZF b (P5/proximal P1) The two anonymous markers sY127 and sY134 are located in the median and distal part of AZFb. According to the present knowledge, in the vast majority of cases the deletion of both markers indicates a complete deletion of the AZFb region. This might be confirmed by using the following second choice markers: sY105 (present) and sY114 (absent) for the proximal border and sY143 (absent) and sY152 (present) for the distal border. If one wishes to determine the breakpoints of the deletion more precisely, in particular to check if the AZFb deletion corresponds to the P5/proximal P1 pattern, which also removes two copies of the DAZ gene (Fig. 1) , the primers described by Repping et al. (2002) should be used. However, it should be pointed out that this is not required for routine clinical diagnosis of a complete deletion of the AZFb region.
AZFc (b2/b4) The two markers sY254 and sY255 are specific for the DAZ gene, which is present in four copies arranged in two complexes of two genes each in head-tohead orientation located in the palindromes P2 and P1 respectively in the reference MSY sequence (Saxena et al., 2000) . The absence of both markers indicates deletion of the entire AZFc region, which removes all copies of DAZ. According to current knowledge, the deletion of only one of these two markers is impossible and should be always regarded as a methodological error. Deletion of individual copies of the DAZ gene is possible but cannot be explored with this protocol. Deletions of only two copies of the DAZ gene have been reported both in infertile and in fertile men (Fernandes et al., 2002; de Vries et al., 2002; Repping et al., 2003) . As the pathophysiological meaning of partial deletions of the AZFc region remains to be determined, this analysis should be considered experimental and is currently not recommended for routine purposes.
The experience accumulated until now has shown that when both markers sY254 and sY255 are deleted, a diagnosis of complete deletion of the AZFc region can be made. As the histological picture of the testis is variable in such cases (Vogt et al., 1996; Luetjens et al., 2002) and sperm can be found in the testis and/or in the ejaculate, TESE/ICSI can be attempted in these patients. Some studies have shown that the AZFc deletion pattern is rather constant, although not always identical (Kuroda-Kawaguchi et al., 2001; Luetjens et al., 2002) . The primers indicated by Kuroda-Kawaguchi et al. (2001) permit the user to determine if the deletion corresponds to the b2/b4 pattern. This analysis, however, will not change the prognosis for the patient and is not necessary for routine purposes.
AZFbc (P5/distal P1 or P4/distal P1) The complete deletion of both AZFb and AZFc regions is indicated by the lack of amplification of all four markers sY127, sY134, sY254 and sY255. The use of more specific markers as indicated by Repping et al. (2002) determine whether the deletion corresponds to the P5/distal P1 or P4/distal P1 pattern but is not necessary for clinical routine, as in view of current knowledge this will not change the prognosis for these patients.
Interpretation of the results, control and repetition of the test
The protocol suggested by these guidelines (see appendix A) has been conceived and optimized so that each of the two multiplex reactions contains a marker for each AZF region. Thus, when a complete deletion occurs in a sample both PCR reactions should show the lack of amplification for the marker specific for that region. While partial deletions of the AZFa and AZFb region, as indicated by the lack of amplification of only one marker for the relevant region, are possible, the elective deletion of only sY254 or sY255 should always be regarded as a methodological error. If only one marker for AZFa or AZFb is deleted, the deletion must first be carefully confirmed (see below) and then the entire region should be studied in more detail. This event, however, is presently regarded as exceptional.
The PCR conditions should be carefully optimized in each laboratory according to the equipment available (e.g. type of Thermocycler) and DNA quality. If the result is ambiguous and/or a technical failure is suspected, the multiplex reaction should be repeated. If the multiplex does not work for a specific DNA sample, the primer set may be run in simplex reactions. If the results of both multiplex PCR consistently speak in favour of a deletion, the deletion is confirmed. If the results of the two multiplexes are not in agreement, the whole set of primers should be repeated in simplex PCR, as there is no reason to repeat the test in the same manner. It is known that simplex PCR is less subject to amplification failure and it is strongly advised to repeat the amplification at a lower annealing temperature. There is no general advice as to the number of repetitions. The test should be repeated until the results are clear and reproducible (good laboratory practice).
Reporting
Reports should be written in a standardized format and should be clear to the non-specialist. Guidelines on how to write reports on the outcome of molecular genetics investigations on a patient can be found at the web site: http://www.emqn.org/bpguidelines.php In general, reports must be clear, concise, accurate, fully interpretative, credible and authoritative. Reports should be typed, word-processed or produced by computer. Handwritten reports are not acceptable. Reports must include the following information:
• Clear identification of the laboratory.
• Date of referral and reporting.
• Patient identification: full name, date of birth and unique laboratory accession/identification number.
• Restatement in some form of the clinical question being asked (e.g. diagnosis of microdeletion of the Y chromosome), and the indication (e.g. azoospermia, ICSI, etc.).
• Tissue studied (e.g. blood, buccal smear, etc).
• Method used (e.g. multiplex PCR amplification).
• Outcome of the analysis: a tabular form of the various STS loci analysed is preferred. Avoid the use of + and ), which can be misinterpreted. Use words instead (e.g. present/ absent, or similar).
• A written interpretation understandable by the nonspecialist.
• Signature of at least one person responsible for the results.
Preferably, all laboratory data are reviewed and all outgoing reports are signed by two independent assessors.
External quality assessment
The laboratories performing AZF diagnostics should join an external quality assessment (EQA) scheme. It is fundamental that the DNA samples received from the organizers of the EQA programme are processed exactly in the same way as patientsÕ samples are handled, including reporting. Results should be returned by mail to the organizers as patient (i.e. DNA sample) reports written in English. E-mail or fax can be used for quick communication, but the final evaluation of the results will be performed exclusively on reports received by mail.
Assessment of the performance of the laboratories participating in the international quality control assessment scheme organized by the EAA and EMQN includes both a general report and individual reports and recommendations to the participants. The results are assessed by independent reviewers. Laboratories, which correctly diagnose and report about the EQA samples receive a certificate.
Clinical relevance of partial deletions and rearrangements of AZFc Very recent data indicate that partial deletions of the AZFc region (Repping et al., 2003; Vogt & Fernandes, 2003) and possibly other types of rearrangements (Fernandes et al., 2004; Repping et al., 2004) occur relatively frequently. While some of these deletions and rearrangements might be of clinical significance, the exact role of such findings in male infertility has not yet been comprehensively analysed. Therefore, this should still be regarded as a very experimental area of infertility genetics and more data are necessary before clear-cut indications can be given for clinical routine.
